https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/dr-wendy-heywood-awarded-investigator-initiated-research-proposal-shire-pharmaceuticals/
Dr Wendy Heywood awarded investigator initiated research proposal from Shire Pharmaceuticals
28 Jun 2016, 2:01 p.m.
Following NIHR Great Ormond Street BRC support, which led to the creation of a high-throughput targeted proteomic urine test, Dr Wendy Heywood has been awarded an industry investigator initiated award from Shire Pharmaceuticals.
This award is for a Great Ormond Street Hospital (GOSH) research nurse to facilitate the clinical sample collection pipeline and manage a database of patient samples and clinical information. This Rare Disease Sample Collection will allow researchers at the UCL Institute of Child Health (ICH) and clinicians from the GOSH Metabolic disease clinic, to find new biomarkers, new disease mechanisms, design new treatments and test patients.
This streamlined ICH-GOSH collaboration will enable translation of current and future new metabolic disease biomarkers to clinical laboratories for use in future clinical trials of existing and novel therapies.
NIHR launches £13.7m investment into brain tumour research
The National Institute for Health and Care Research (NIHR) has announced a £13.7 million investment that will support ground-breaking research to develop novel brain tumour treatments in the UK.
New consortium aims to help improve care for arthritis patients
A new UK-led research group, including Great Ormond Street Hospital and University College London, aims to improve the lives of children, young people and adults with arthritis by defining for the first time what being in ‘remission’ from arthritis truly
Update for patients and families on industrial action - December 2025
As you may be aware, some of our Resident Doctors will be taking part in planned industrial action from 7am on Wednesday 17 December to 7am on Monday 22 December.
‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-Cell leukaemia
A groundbreaking new treatment using gene-edited immune cells, developed at GOSH and UCL has shown promising results in helping children and adults fight a rare and aggressive cancer